Risk of acute atherosclerotic cardiovascular disease in patients with acute and chronic pancreatitis.

In this study, we used research data from the health insurance program, and it covers at least 99% of residents in Taiwan. The research database included the patient’s basic characteristics, examination, diagnoses, prescriptions, and treatments of inpatient and outpatient medical services. The detailed description and reviews of this database were reported previously 7 , 8 , 10 , 11 . Our study waived the need of informed consent and it was approved by the institutional review board of Taipei Medical University (TMU-JIRB-201701050; TMU-JIRB-201705063; TMU-JIRB-201705065; TMU-JIRB-201808012; TMU-JIRB-201912046). All methods were carried out in accordance with relevant guidelines and regulations. We conducted this retrospective cohort study using a random sample of 1 million beneficiaries from the research database and there is no direct participation of patients in the current study. The database of Taiwan’s National Health Insurance was available since 1996. We identified 2737 patients aged over 20 years who were newly diagnosed with pancreatitis in the period 2000–2008; 10,948 persons without a history of pancreatitis were selected as the control group, with frequency matching by age and sex (case–control ratio nearly 1:4). In this study, the wash-out period was 4 years (confirming both cohorts had no physician’s diagnosis of pancreatitis within past 4 years). To strictly identify pancreatitis cases, we defined pancreatitis by requiring inpatient care with pancreatitis as the physician's primary diagnosis. The pancreatitis and non-pancreatitis cohorts had no history of acute ASCVD at the start, and both were followed up from the index date until December 31, 2013, or until they were censored because of death. The event of acute ASCVD was considered the outcome during the follow-up period. The low-income patients were identified according to the criteria from the Ministry of Health and Welfare. For indentifying medical conditions and major outcomes, we used the physician’s diagnoses and the International Classification of Diseases-Clinical Modification, 9th edition (ICD-9-CM) including acute pancreatitis (code 577.0), chronic pancreatitis (code 577.1), stroke (codes 430–437), acute myocardial infarction (codes 410), diabetes (codes 250), hypertension (codes 401–405), mental disorders (codes 290–319), alcohol-related illness (codes 291, 303, 305, 571.0, 571.1, 571.2, 571.3), liver cirrhosis (codes 571.2, 571.5, 571.6), hyperlipidemia (codes 272.0, 272.1, and 272.2), chronic obstructive pulmonary disease (codes 491, 492, 496), and cholecystitis (codes 574). The insurance codes (D8, D9) were used to identify medical dialysis of kidney. Based on our previous drug-related studies 12 – 15 , we defined people who visited medical care (included outpatient, inpatient, and emergency care) and received a physician’s prescription for metformin under the coverage of Taiwan’s National Health Insurance Program. The prescription of metformin was identified from the medication records of payment of Taiwan’s National Health Insurance Program. In this study, we check the date of prescription of metformin and confirm that the use of metformin fall at time point after an attack of pancreatitis. We collected and calculated the cumulative use of metformin during the follow-up period. To avoid immortal time bias (which might result in overestimation of the intervention’s beneficial effects) in the metformin group, we followed up the pancreatitis patients from the first date when they received metformin after index the diagnosis of pancreatitis until December 31, 2013 or until an event (developed a acute ASCVD, lost to follow-up, or death). The follow-up time, in person-years, was calculated for each pancreatitis patient from the index date to the end-point. We compared the risk of an incident acute ASCVD during the follow-up period between the pancreatitis patients who received metformin treatment and those who did not. We compared sociodemographic factors (age, sex and low income) and coexisting medical conditions (diabetes, hypertension, mental disorders, alcohol-related illness, liver cirrhosis, hyperlipidemia, chronic obstructive pulmonary disease, cholecystitis, and renal dialysis) in the cohorts of patients with and without pancreatitis using chi-square tests. In the overall population and subgroup analysis stratified by age and sex, we used multivariate Cox proportional hazard models to calculate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for acute ASCVD associated with pancreatitis. The effects of pancreatitis-related diseases and metformin medication on the risk of acute ASCVD in patients with pancreatitis were also evaluated using Cox proportional hazard models.

Under the frequency matching procedure, there were no significant differences in age or sex between subjects with and without pancreatitis (Table 1 ). Higher proportions of low income, diabetes, hypertension, mental disorders, alcohol-related illness, liver cirrhosis, hyperlipidemia, chronic obstructive pulmonary disease, cholecystitis, and renal dialysis were found in pancreatitis patients than in subjects without pancreatitis (all p < 0.05). Table 1 Baseline characteristics of people with and without pancreatitis. No pancreatitis (n = 10,825) Pancreatitis (n = 2678) p-value n (%) n n (%) Sex Female 3284 (30.3) 808 3284 (30.3) Male 7541 (69.7) 1870 7541 (69.7) Age, years 20–29 808 (7.5) 201 808 (7.5) 30–39 2311 (21.4) 575 2311 (21.4) 40–49 2585 (23.9) 641 2585 (23.9) 50–59 1661 (15.3) 411 1661 (15.3) 60–69 1493 (13.8) 365 1493 (13.8) 70–79 1341 (12.4) 336 1341 (12.4) ≥ 80 626 (5.8) 149 626 (5.8) Low income No 10,488 (96.9) 2486 10,488 (96.9) Yes 337 (3.1) 192 337 (3.1) Medical conditions Diabetes 986 (9.1) 600 986 (9.1) Hypertension 1937 (17.9) 538 1937 (17.9) Mental disorders 1034 (9.6) 401 1034 (9.6) Alcohol-related illness 91 (0.8) 294 91 (0.8) Liver cirrhosis 175 (1.6) 181 175 (1.6) Hyperlipidemia 419 (3.9) 156 419 (3.9) COPD 351 (3.2) 121 351 (3.2) Cholecystitis 121 (1.1) 120 121 (1.1) Renal dialysis 61 (0.6) 51 61 (0.6) COPD chronic obstructive pulmonary disease. Baseline characteristics of people with and without pancreatitis. COPD chronic obstructive pulmonary disease. As shown in Table 2 , a higher incidence of acute ASCVD was found in patients with acute (11.8 per 1000 person-years) and chronic (17.7 per 1000 person-years) pancreatitis than in those without pancreatitis (6.81 per 1000 person-years, p < 0.0001) during the follow-up period. The corresponding HR of acute ASCVD associated with acute pancreatitis and chronic pancreatitis were 1.76 (95% CI 1.47–2.12) and 3.42 (95% CI 1.69–6.94), respectively. Among people with 1 (HR 2.01, 95% CI 1.49–2.71) and ≥ 2 (HR 2.02, 95% CI 1.53–2.67) medical conditions, pancreatitis was associated with the risk of acute ASCVD. Table S1 showed the stratified analyses (by sex and age) for the risk of acute ASCVD in patients with acute and chronic pancreatitis. Table 2 The long-term risk of acute ASCVD for people with and without pancreatitis. Long-term risk of acute ASCVD n Events Person-years Incidence b HR 95% CI a No pancreatitis 10,825 647 94,957 6.81 1.00 Reference Pancreatitis 2678 267 22,335 12.0 1.80 1.50–2.15 Acute pancreatitis 2607 257 21,769 11.8 1.76 1.47–2.12 Chronic pancreatitis 71 10 565 17.7 3.42 1.69–6.94 0 medical condition No pancreatitis 7196 195 63,237 3.08 1.00 Reference Pancreatitis 1330 46 10,880 4.23 1.22 0.83–1.81 Acute pancreatitis 1295 44 10,597 4.15 1.17 0.78–1.76 Chronic pancreatitis 35 2 283 7.07 3.14 0.78–12.7 1 medical condition No pancreatitis 2411 231 21,397 10.8 1.00 Reference Pancreatitis 764 91 6757 13.5 2.01 1.49–2.71 Acute pancreatitis 747 88 6604 13.3 2.00 1.48–2.70 Chronic pancreatitis 17 3 153 19.6 2.70 0.66–11.0 ≥ 2 medical conditions No pancreatitis 1218 221 10,322 21.4 1.00 Reference Pancreatitis 584 130 4698 27.7 2.02 1.53–2.67 Acute pancreatitis 565 125 4569 27.4 1.98 1.50–2.62 Chronic pancreatitis 19 5 129 38.8 4.06 1.48–11.1 ASCVD atherosclerotic cardiovascular disease, CI confidence interval, HR hazard ratio. a Adjusted for all covariates listed in Table 1 . b Per 1000 person-years. The long-term risk of acute ASCVD for people with and without pancreatitis. ASCVD atherosclerotic cardiovascular disease, CI confidence interval, HR hazard ratio. a Adjusted for all covariates listed in Table 1 . b Per 1000 person-years. Compared with people without pancreatitis (Table 3 ), those with acute pancreatitis who had alcohol-related illness (HR 4.66, 95% CI 3.24–6.70), liver cirrhosis (HR 4.44, 95% CI 3.05–6.47), diabetes (HR 2.61, 95% CI 2.03–3.36), and cholecystitis (HR 2.24, 95% CI 1.30–3.87) were more likely to have acute ASCVD. The increased risk of ASCVD was found in patients with chronic pancreatitis who had alcohol-related illness (HR 9.49, 95% CI 3.78–23.8), liver cirrhosis (HR 7.31, 95% CI 1.81–29.5), and diabetes (HR 6.89, 95% CI 2.18–21.8). In patients with acute pancreatitis, the use of metformin ≥ 2 times (HR 0.30, 95% CI 0.17–0.50) was associated with a reduced risk of ASCVD. Table 3 The effects of medical conditions on long-term risk of acute ASCVD in patients with pancreatitis. Long-term risk of acute ASCVD n Events Incidence b HR 95% CI People without pancreatitis 10,825 647 6.81 1.00 Reference Pancreatitis patients had ARI 294 53 22.7 4.89 3.44–6.96 Acute pancreatitis patients had ARI 279 48 21.4 4.66 3.24–6.70 Chronic pancreatitis patients had ARI 15 5 50.5 9.49 3.78–23.8 Pancreatitis patients had liver cirrhosis 181 35 22.9 4.53 3.14–6.54 Acute pancreatitis patients had liver cirrhosis 171 33 22.8 4.44 3.05–6.47 Chronic pancreatitis patients had liver cirrhosis 10 2 25.6 7.31 1.81–29.5 Pancreatitis patients had diabetes 600 97 18.9 2.67 2.08–3.42 Acute pancreatitis patients had diabetes 586 93 18.4 2.61 2.03–3.36 Chronic pancreatitis patients had diabetes 14 4 40.8 6.89 2.18–21.8 Pancreatitis patients had cholecystitis 120 31 34.5 2.18 1.26–3.76 Acute pancreatitis patients had cholecystitis 118 30 33.9 2.24 1.30–3.87 Chronic pancreatitis patients had cholecystitis 2 1 78.4 – – People had pancreatitis Without use of metformin 2293 242 12.8 1.00 Reference Use 1 time of metformin 43 4 9.83 0.45 0.16–1.23 Use ≥ 2 times of metformin 342 21 6.80 0.28 0.16–0.47 People had acute pancreatitis Without use of metformin 2228 232 12.7 1.00 Reference Use 1 time of metformin 43 4 9.83 0.46 0.17–1.26 Use ≥ 2 times of metformin 336 21 6.91 0.30 0.17–0.50 People had chronic pancreatitis Without use of metformin 65 10 19.5 1.00 Reference Use 1 time of metformin 0 0 0.0 – – Use ≥ 2 times of metformin 6 0 0.0 – – ARI alcohol-related illness, ASCVD atherosclerotic cardiovascular disease, CI confidence interval, HR hazard ratio. a Adjusted for all covariates listed in Table 1 . b Per 1000 person-years. The effects of medical conditions on long-term risk of acute ASCVD in patients with pancreatitis. ARI alcohol-related illness, ASCVD atherosclerotic cardiovascular disease, CI confidence interval, HR hazard ratio. a Adjusted for all covariates listed in Table 1 . b Per 1000 person-years. During the follow-up period (Table 4 ), patients with acute pancreatitis had an increased risk of acute myocardial infarction (HR 1.75, 95% CI 1.11–2.74) or stroke (HR 1.76, 95% CI 1.44–2.15). The risks of hemorrhagic stroke (HR 2.14, 95% CI 1.42–3.23), ischemic stroke (HR 1.46, 95% CI 1.05–2.02), and other stroke (HR 1.62, 95% CI 1.17–2.23) were associated with acute pancreatitis. Chronic pancreatitis was associated with risk of stroke (HR 4.20, 95% CI 2.07–8.56), included ischemic stroke (HR 6.20, 95% CI 2.25–17.1) and other stroke (HR 3.78, 95% CI 1.19–12.0). Table 4 Long-term risk of acute myocardial infarction and stroke in patient with pancreatitis. Long-term risk of acute ASCVD n Events Person-years Incidence b HR 95% CI a Risk of AMI No pancreatitis 10,825 98 97,590 1.00 1.00 Reference Pancreatitis 2678 50 23,325 2.14 1.71 1.09–2.68 Acute pancreatitis 2607 50 22,711 2.20 1.75 1.11–2.74 Chronic pancreatitis 71 0 614 0 – – Risk of all stroke No pancreatitis 10,825 549 95,411 5.75 1.00 Reference Pancreatitis 2678 217 22,505 9.64 1.81 1.49–2.21 Acute pancreatitis 2607 207 21,939 9.44 1.76 1.44–2.15 Chronic pancreatitis 71 10 565 17.7 4.20 2.07–8.56 Risk of hemorrhagic stroke No pancreatitis 10,825 90 97,668 0.92 1.00 Reference Pancreatitis 2678 50 23,284 2.15 2.12 1.41–3.19 Acute pancreatitis 2607 49 22,678 2.16 2.14 1.42–3.23 Chronic pancreatitis 71 1 606 1.65 1.49 0.20–10.9 Risk of ischemic stroke No pancreatitis 10,825 239 96,872 2.47 1.00 Reference Pancreatitis 2678 78 23,143 3.37 1.54 1.12–2.12 Acute pancreatitis 2607 73 22,550 3.24 1.46 1.05–2.02 Chronic pancreatitis 71 5 594 8.42 6.20 2.25–17.1 Risk of other stroke No pancreatitis 10,825 220 96,960 2.27 1.00 Reference Pancreatitis 2678 89 23,067 3.86 1.67 1.21–2.29 Acute pancreatitis 2607 85 22,473 3.78 1.62 1.17–2.23 Chronic pancreatitis 71 4 595 6.72 3.78 1.19–12.0 ASCVD atherosclerotic cardiovascular disease, AMI acute myocardial infarction, CI confidence interval, HR hazard ratio. a Adjusted for all covariates listed in Table 1 . b Per 1000 person-years. Long-term risk of acute myocardial infarction and stroke in patient with pancreatitis. ASCVD atherosclerotic cardiovascular disease, AMI acute myocardial infarction, CI confidence interval, HR hazard ratio. a Adjusted for all covariates listed in Table 1 . b Per 1000 person-years. Table S2 showed the stratified analyses for the risk of acute myocardial infarction in patients with acute and chronic pancreatitis. Table S3 showed the stratified analyses for the risk of stroke in patients with acute and chronic pancreatitis.

Our population-based cohort study showed that patients with pancreatitis had increased risks of acute ASCVD, including acute myocardial infarction and stroke. The association between pancreatitis and acute ASCVD was significant in various subgroups. Patients with pancreatitis showed higher risks of acute ASCVD as well as complications such as liver cirrhosis, diabetes, and cholecystitis. Our study also reported the safety of metformin in patients with pancreatitis. The association between pancreatitis and acute ASCVD could not be clarified completely in this observational study, we reviewed some relevant studies to explain the mechanism. First, the endothelium is considered a regulator of vascular homeostasis. Inflammation may cause endothelial dysfunction, which contributes to the initiation and progression of atherosclerosis 2 . Inflammation of the pancreas causes the aggregation of neutrophils, macrophages, and injured pancreatic acinar cells, releasing cytokines such as interleukin (IL)-10, IL-6, tumor necrosis factor-α, transforming growth factor-β, platelet-derived growth factor, and the chemokine monocyte chemoattractant protein-1 11 , 16 . These inflammatory cytokines play a pivotal role in the pathogenesis of atherosclerosis 17 , 18 . These inflammatory cells further enhance inflammation and tend to precipitate unstable or ruptured atherosclerotic plaques. Second, severe hemodynamic disturbances such as profound hypotension and hypovolemia decrease coronary artery or cerebrovascular perfusion 8 . Third, metabolic disturbances include hyperglycemia and hyperlipidemia, which exert equal stimulatory effects on platelet activation and vascular events 19 , 20 . The long-term effect of gallstone disease on cardiovascular outcomes is highly debated 21 – 24 . Although we investigated that pancreatitis patients with cholecystitis had increased risk of acute ASCVD in this study, we recommend further prospective studies to examine this epiphenomenon. Post-pancreatitis diabetes mellitus is an exemplar secondary diabetes that represents a sequela of pancreatitis—the most common disease of the exocrine pancreas 25 , 26 . People have at least two-fold higher lifetime risk of developing diabetes after an attack of pancreatitis than those in the general population 25 . Both basic research and population-based study provide strong evidence suggesting that hypertriglyceridemia could be involved in the pathophysiology of acute ASCVD 20 , 27 , 28 . We considered that the effect of hypertriglyceridemia as the etiology of acute pancreatitis as well as a risk factors for severe disease and the potential link with cardiovascular disorders. It has been shown that the use of metformin is beneficial for reducing the risk of cardiovascular events in diabetic patients 24 , 29 . Growing evidence suggests that metformin has a protective effect against acute ASCVD beyond its hypoglycemic effects 29 , 30 . Possible explanations for the cardio-protective role of metformin may be due to its pleiotropic effects, including antioxidant, improved endothelial cell function, decreased smooth muscle cell migration, decreased cholesterol deposition and anti‑inflammatory activities, which may reduce atherosclerotic plaques 29 , 31 . Furthermore, metformin has been reported to reduce the levels of certain inflammatory cytokines involved in pancreatitis, as mentioned previously 30 . Our study is the first to report that the use of metformin is associated with a reduced risk of acute ASCVD in patients with pancreatitis. However, these interesting findings need to be verified by future randomized clinical trials. Among people with post-pancreatitis diabetes mellitus, ever users of metformin had a significantly lower mortality, whereas ever-users of insulin did not have a significantly changed risk of mortality compared with never users of antidiabetic medications 32 . Therefore, metformin promotes a survival benefit in people with post-pancreatitis diabetes mellitus. Previous studies found that 23% and 30% of people after the first attack of acute pancreatitis and chronic pancreatitis developed post-pancreatitis diabetes mellitus, respectively 25 . Individuals with post-pancreatitis diabetes mellitus had higher rate of all-cause mortality than those with type 2 diabetes and metformin monotherapy is recommended as the first-line therapy for post-pancreatitis diabetes mellitus 25 . Emerging data suggest that the acute, recurrent acute and chronic forms of pancreatitis represent a disease continuum 33 . Although clinical factors and pancreatic enzymes have been identified, discriminating between acute and chronic pancreatitis in individual patients remains difficult. We included patients with pancreatitis irrespective of chronicity to ensure diagnostic accuracy, and our report is comparable with previous studies 7 , 10 , 11 , 34 , 35 . The limitations of this present study are as follows. First, information on each individual’s socioeconomic characteristics, lifestyle factors, physical examination results, laboratory measurements, and imaging results was unavailable in Taiwan’s National Health Insurance database. Smoking is an important factor for the association between pancreatitis and ASCVD. It is one of our study limitations that the information of smoking is not available in the database of Taiwan’s National Health Insurance. Second, although our results showed that use of metformin is associated with a decreased risk of acute ASCVD, the compliance of medication intake is one of study limitations. In conclusion, we reported that patients with acute or chronic pancreatitis were more likely to have acute ASCVD, particularly those with pancreas-related comorbidities, while the use of metformin is associated with a reduced risk of acute ASCVD. Our results highlight the importance of using a multidisciplinary team to adopt an integrated approach to prevent patients with pancreatitis from developing acute ASCVD. Further clinical trials are warranted to provide more evidence regarding the beneficial effects of metformin on reducing acute ASCVD in this susceptible population.

Coronary artery disease and stroke are the second and third leading causes of death in the world, respectively 1 . Atherosclerosis is a common pathological process characterized by the accumulation of lipids and lymphocytes/macrophages in the walls of large and medium-sized arteries 2 , 3 . Atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease and ischemic stroke, accounts for the majority of cardiovascular mortality, imposes enormous economic burdens and continues to be a major public health issue worldwide 1 , 4 . Pancreatitis, which is characterized by inflammation of the pancreas, have been classified in either acute, recurrent acute or chronic forms 5 , 6 . Acute pancreatitis often leads to a number of sequelae long after clinical resolution, and should no longer be considered a self-limited disease 6 . Around 21% of patients suffering a first acute pancreatitis will develop recurrent acute pancreatitis. Of those developing recurrent acute pancreatitis, up to 36% will develop chronic pancreatitis 5 . Alcohol abuse and gallstones are common etiologies for acute pancreatitis, accounting for over 80% of all cases 5 . In most areas, the gallstone is the most common etiology following by idiopathic etiology. Acute pancreatitis is associated with profound hypotension, hyperglycemia and increased circulating levels of inflammatory cytokines/proteolytic enzymes 7 , 8 . Chronic pancreatitis is a chronic inflammatory and fibrotic disease of the pancreas with a prevalence of 42 to 73 per 100,000 adults in the United States 9 . Chronic pancreatitis often results in chronic abdominal pain and is most commonly caused by excessive alcohol use, smoking, or genetic mutations 9 . Suggestions of treatment included alcohol and smoking cessation, pain control, replacement of pancreatic insufficiency, or mechanical drainage of obstructed pancreatic ducts for some patients 5 , 9 – 11 . Some studies have suggested that patients with acute or chronic pancreatitis are more likely to have acute ASCVD, including acute myocardial infarction and stroke, compared with those without pancreatitis 7 , 8 , 10 , 11 . However, there is heterogeneity in these previous reports because of study limitations, such as small sample sizes 8 , inadequate control of confounding factors 7 , 8 , 10 , 11 , and unclear definitions of pancreatitis cases 7 , 9 , 11 . In addition, the influence of pancreatitis severity on the risk of acute ASCVD is unclear. Using research data from the health insurance program in Taiwan, we conducted this retrospective cohort study to evaluate the risk of acute ASCVD in patients with acute and chronic pancreatitis.

Supplementary Tables. Supplementary Tables.